A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...
We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...
10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Alongside the amended certificate, Metsera, Inc. also updated its bylaws.
Shares of APO stock traded down $1.49 during mid-day trading on Friday, reaching $163.39. The company’s stock had a trading volume of 2,484,780 shares, compared to its average volume of ...
17d
24/7 Wall St. on MSNInsider Buying Surges in February, Especially in These 6 StocksIn January, the number of notable insider purchases was somewhat muted. But with the turn of the calendar page, insider enthusiasm has returned. Warren Buffett continues to build a stake in a media ...
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) ("Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results